Here are the latest stories being discussed in biopharma today:

1. The U.S. Food and Drug Administration (FDA) has finalized a new rule authorizing its oversight of laboratory-based tests. Lab groups red-flagged the move, voicing concerns over potential innovation setbacks and patient access. The over-500-page rule has been designed to ensure patient safety and detail the four-year transition process for laboratories to comply.

2. Merck, the multinational pharmaceutical company, unveiled further data in support of its 21-valent pneumonia vaccine, V116. It believes its treatment offers superior broad-spectrum protection for older adults than Pfizer’s 20-valent Prevnar 20. The FDA is scheduled to deliver its decision on June 17, potentially reigniting the rivalry between the two pharmaceutical giants.

3. According to a recent PatientView survey, Pharma’s reputation among patient advocacy groups has suffered a dip for the first time in five years. With the industry score slipping to 57% from 60% the previous year, it marks a potential end to Pharma’s improved reputation run.

4. Novo Nordisk’s weekly insulin application will undergo scrutiny by the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on May 24. The drug candidate, insulin icodec, is a proposed solution to cut patient’s standard seven basal insulin injections per week to just one.

5. In collaboration with Regeneron, Sanofi has launched a renewed advertising campaign for its Dupixent asthma product. The campaign focuses on the benefits of ‘better breathing’ for individuals’ daily lives and uses humor to engage its target audience.

6. WuXi AppTec, the Shanghai-based pharmaceutical company, is committed to protecting its clients’ intellectual property rights amidst claims of data sharing with Chinese authorities. CEO Ge Li asserted its dedication to customer prioritization, IP protection, and strict adherence to international laws and regulations.